摘要
目的回顾性分析经动脉灌注国产盐酸吉西它滨(Gemcitabine hydrochloride,商品名泽菲)和5-氟尿嘧啶(5-fluorouracil,5-Fu)治疗中晚期胰腺癌临床疗效。方法20例中晚期胰腺癌患者接受动脉灌注泽菲和5-Fu化疗。治疗后观察肿瘤情况、临床受益反应(CBR)和病人的生存时间。结果20例患者中PR2例(10%),SD5例(25%),6例无法评价。频数分布法计算中位生存期为5.42个月,中位进展期为2.89个月。临床受益率为35%(与文献相比P<0.001)。结论经动脉灌注泽菲和5-Fu治疗中晚期胰腺癌显示出良好的临床受益反应;并能有效延长病人的生存时间。
Objective To retrospectively analyze the effectiveness of transarterial infusion chemotherapy of gemcitabine and 5-fluorouracil for management of advanced pancreatic carcinoma. Methods Gemcitabine and 5- fluorouracil was administered to 20 patients with advanced pancreatic carcinoma via an interarterial catheter. Then the tumor response rate and clinical benefit rate were observed. Results Of 2 patient （10%） obtained partial response （PR）, and 5 patients （25%） achieved no change of their disease, median survival period was 5.42 months, The median time to progression was 2.89 months. No serious side effects were observed. Clinical benefit response （CBR） was 35%. Conclusions Transarterial infusion of gemcitabine and 5-fluorouracil appears well tolerated and promising CBR in patients with advanced pancreatic carcinoma.
出处
《海南医学》
CAS
2007年第6期26-28,共3页
Hainan Medical Journal
关键词
胰腺癌
吉西它滨
5-氟尿嘧啶
动脉灌注
疗效
临床受益反应
Pancreatic carcinoma
Gemcitabine
5-fluorouracil
Transcatheter arterial infusion
efficiency
Clinical benefit response
